Global Influenza Diagnostics Market Size (2024 - 2029)

The influenza diagnostics market is experiencing growth driven by factors such as the increasing prevalence of influenza, the demand for early diagnosis, and enhanced research funding. The market's expansion has been influenced by the need for accurate diagnostics, especially during the COVID-19 pandemic, due to the similarities between the two viruses. Despite these growth drivers, the market faces challenges from stringent FDA regulations that impact the approval of rapid antigen tests.

Market Size of Global Influenza Diagnostics Industry

Influenza Diagnostics Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 1.09 Billion
Market Size (2029) USD 1.43 Billion
CAGR (2024 - 2029) 5.60 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Influenza Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Influenza Diagnostics Market Analysis

The Global Influenza Diagnostics Market size is estimated at USD 1.09 billion in 2024, and is expected to reach USD 1.43 billion by 2029, growing at a CAGR of 5.60% during the forecast period (2024-2029).

COVID- 19 has significantly impacted the influenza diagnostics market due to the closing of manufacturing facilities due to lockdowns, unfavorable regulations and guidelines changes, and supply chain disruptions globally. Additionally, there are several similarities between COVID-19 and influenza, such as both are contagious viruses and show similar symptoms of respiratory illness. As COVID-19 affects a patient's respiratory system, it is necessary to diagnose influenza too for safety purposes. This has increased the testing for influenza during the pandemic.

The rising prevalence of influenza and related chronic diseases increased research funding for influenza diagnostics, and rising demand for early diagnosis and control of influenza are all factors driving the market growth. Influenza is recognized as a significant cause of morbidity and mortality in humans, prompting the development and implementation of diagnostics to reduce health and economic consequences. According to the updates from January 2022 by the Centers for Disease Control and Prevention, flu caused 9 million 41 million illnesses, 140,000-710,000 hospitalizations, and 12,000-52,000 deaths annually in the United States between 2010 and 2020.

Furthermore, according to the World Health Organization (WHO) updates from February 2021, during the years 2021-2022, WHO GISRS laboratories tested over 490 516 specimens. A total of 12 368 people tested positive for influenza viruses, with 8 423 (68.1%) being influenza A and 3 945 (31.9%) being influenza B. Various initiatives and research funding are assisting in the market's expansion. For example, the National Institute of Allergy and Infectious Diseases (NIAID) has funded a diverse range of influenza research, including studies that are helping to develop vaccines, diagnostics, and therapeutics for seasonal and pandemic influenza.

Moreover, in September 2021, DiaSorin Molecular LLC received a CE mark for its Simplexa COVID-19 & Flu A/B Direct kit. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, and influenza B virus from the same patient sample in one reaction well. Also, in December 2021, Roche planned to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets that accept CE Mark.

However, ensuring that all the rapid antigen flu tests meet new Food and Drug Administration (FDA) requirements for approval is critical. Hence, the stringent FDA regulations act as significant restraints for the market.

Influenza Diagnostics Industry Segmentation

Influenza, also known as flu, is a highly contagious infectious disease caused by a virus. This is an infection of the respiratory passages, which causes fever and severe aches. The influenza diagnostic market includes the tests that are conducted for the diagnosis of influenza cases. As per the scope of this report, only the test kits and reagents used for the diagnosis of influenza have been considered for calculating the total market size. The Influenza Diagnostics Market is segmented by Test Type (Traditional Diagnostic Test and Molecular Diagnostic Assay), End User (Hospital, Laboratories, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across significant regions globally. The report offers the value (USD million) for the above segments.

By Test Type
Traditional Diagnostic Test
Rapid Influenza Diagnostic Test (RIDT)
Viral Culture
Direct Fluorescent Antibody (DFA) Test
Serological Assay
Molecular Diagnostic Assay
RT-PCR
Nucleic Acid Sequence-based Amplification (NASBA) Test
Loop-mediated Isothermal Amplification-based Assay (LAMP)
Simple Amplification-based Assay (SAMBA)
Other Molecular Diagnostic Assays
By End User
Hospital
Laboratories
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Influenza Diagnostics Market Size Summary

The influenza diagnostics market is poised for significant growth over the forecast period, driven by the increasing prevalence of influenza and the demand for early diagnosis and control measures. The market has been influenced by the COVID-19 pandemic, which highlighted the need for influenza testing due to the similarities in symptoms and the impact on respiratory health. This has led to heightened research funding and development efforts aimed at improving diagnostic capabilities. The market is characterized by the presence of rapid influenza diagnostic tests (RIDTs), which are favored for their quick results and ease of use, despite some limitations in sensitivity. North America currently leads the market, supported by a high prevalence of influenza and the widespread availability of RIDTs, alongside ongoing product launches and public health initiatives.

The competitive landscape of the influenza diagnostics market is marked by the presence of several key players, including Coris BioConcept, DiaSorin SpA, and F. Hoffmann-La Roche AG, among others. These companies are actively involved in product development and strategic initiatives to enhance their market position. Recent advancements include the introduction of multiplex tests that can simultaneously detect multiple viruses, such as SARS-CoV-2 and influenza A/B, which are expected to drive market growth. Regulatory challenges, particularly concerning FDA approvals, remain a significant consideration for market participants. Overall, the market is expected to expand as a result of ongoing research, technological advancements, and the increasing need for effective influenza diagnostics.

Explore More

Global Influenza Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Influenza

      2. 1.2.2 Growth in Research Funding for Influenza Diagnostics

      3. 1.2.3 Rising Demand for Early Diagnosis and Control of Influenza

    3. 1.3 Market Restraints

      1. 1.3.1 Rising Healthcare Costs Limiting the Usage of Novel Influenza Diagnostic Techniques

      2. 1.3.2 Stringent Government Regulations

      3. 1.3.3 Variability in Sensitivity and Specificity among Influenza Diagnostic Tests

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Test Type

      1. 2.1.1 Traditional Diagnostic Test

        1. 2.1.1.1 Rapid Influenza Diagnostic Test (RIDT)

        2. 2.1.1.2 Viral Culture

        3. 2.1.1.3 Direct Fluorescent Antibody (DFA) Test

        4. 2.1.1.4 Serological Assay

      2. 2.1.2 Molecular Diagnostic Assay

        1. 2.1.2.1 RT-PCR

        2. 2.1.2.2 Nucleic Acid Sequence-based Amplification (NASBA) Test

        3. 2.1.2.3 Loop-mediated Isothermal Amplification-based Assay (LAMP)

        4. 2.1.2.4 Simple Amplification-based Assay (SAMBA)

        5. 2.1.2.5 Other Molecular Diagnostic Assays

    2. 2.2 By End User

      1. 2.2.1 Hospital

      2. 2.2.2 Laboratories

      3. 2.2.3 Other End Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East & Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East & Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Influenza Diagnostics Market Size FAQs

The Global Influenza Diagnostics Market size is expected to reach USD 1.09 billion in 2024 and grow at a CAGR of 5.60% to reach USD 1.43 billion by 2029.

In 2024, the Global Influenza Diagnostics Market size is expected to reach USD 1.09 billion.

Influenza Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)